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Editorial on the Research Topic
Recent Advances in the Controversial Human Pathogens Pneumocystis, Microsporidia
and Blastocystis
Pneumocystis spp. are ubiquitous atypical fungi that develop extracellularly in the alveolar
cavities of mammalian lungs with a not-completely defined lifecycle (Cushion, 2010). Similarly,
microsporidia are a diverse group (>1,400 species) of obligate intracellular fungi, with a broad
range of vertebrate and invertebrate hosts and poorly understood mechanisms of invasion, growth
and reproduction (Han andWeiss, 2017). Blastocystis spp. are ubiquitous anaerobic eukaryotes that
have a unique phylogenetic origin but are widely present in various mammals, including humans
(Scanlan and Stensvold, 2013). All these organisms have environmental stages required for the
initiation of infection in new hosts, and were previously considered protozoa. Further controversies
remain on the species structure, zoonotic potential, transmission routes, and pathogenicity/clinical
significance of each group of organisms (Didier, 2005; Morris and Norris, 2012; Scanlan and
Stensvold, 2013). Recently, with the development of various molecular tools for the identification
and characterization and the availability of whole genome sequences, metagenomics tools, animal
models and/or cultivation, there have been significant advances in our understanding of the biology
and epidemiology of these controversial pathogens. The 2019–2020 Research Topic on Recent
Advances in the Controversial Human Pathogens Pneumocystis, Microsporidia and Blastocystis has
published 11 manuscripts, nine in Frontiers in Microbiology and two in Frontiers in Public Health.
This topic aimed to gather articles from research groups who are active on these neglected and
opportunistic pathogens. They highlight the potential of new tools and approaches in resolving
some longstanding issues. These research articles are contributions from several major research
groups in these three areas, significantly improving our knowledge of P. jirovecii, microsporidia
and Blastocystis infections in different contexts.
PNEUMOCYSTIS
The articles gathered in this Research Topic addressed issues in epidemiology and risk factors of
PCP in industrialized nations and low-income countries, especially on the genetic diversity of the
pathogen. Attention was given to the use of modern diagnostic approaches. The pathogenesis of
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PCP and host defenses against P. jirovecii and its relationship
with new therapies were discussed.
Knowing the prevalence and risk factors of PCP is a basic
requirement for the prevention and control of the disease.
Pereira-Díaz et al. conducted a nationwide study in Spain
with this objective. It was a descriptive study of PCP patients
registered in the Hospital Discharge Records Database of the
country between 2008 and 2012. There was an increase in the
annual incidence of PCP cases in non-HIV-infected patients
and a decrease in HIV-infected patients. Risk factors identified
in the HIV-negative group included hematological neoplasm,
chronic lung diseases and non-hematological cancers. The mean
mortality and the hospitalization costs observed were higher
in non-HIV-infected patients with PCP than in HIV-infected
patients with PCP. These observations indicate that PCP is an
emerging problem in non-HIV-infected patients.
In another retrospective study of specimens from PCP
patients from Réunion (a French island in the Indian Ocean),
French Guiana (a French South American territory) and
Brest (Brittany, metropolitan France), Le Gal et al. compared
multilocus genotypes of P. jirovecii among these very different
populations. A multilocus sequence typing (MLST) based on
three distinct loci of P. jirovecii was used for the analysis
of specimens. The data generated revealed significant genetic
diversity of P. jirovecii in the islands and the existence of
geographically segregated pathogen populations.
Morilla et al. addressed the issue of colonization by P.
jirovecii. They analyzed epidemiological data from PCP patients
and P. jirovecii-colonized individuals in Spain and data on the
distribution of superoxide dismutase (SOD) genotypes of P.
jirovecii isolates. Only two SOD genotypes were found in the
country, with one being the dominant genotype in the colonized
individuals. SOD is a single copy nuclear gene commonly used
in genotyping studies. Based on the data obtained, the authors
concluded that although SOD-PCR is not an attractive tool
for genotyping P. jirovecii, it could be useful in distinguishing
colonization from PCP.
The diagnosis of PCP relies heavily on microscopic
visualization of organisms or DNA detection in respiratory
specimens obtained by invasive/costly techniques, which are
difficult to implement in low-income countries. As an alternative,
blood biomarkers, reflecting the host-pathogen interaction, were
tested (Matos and Esteves, 2016). Elevated serum levels of (1-3)-
β-D-Glucan (cell wall component of P. jirovecii cystic forms
or ascus) were related to PCP and proposed as marker of the
disease, especially in non-HIV-infected immunocompromised
patients (Esteves et al., 2014; Matos and Esteves, 2016). Recent
studies propose the immunodiagnosis of PCP, based on the
detection of IgM anti-P. jirovecii antibodies, using recombinant
synthetic antigens, as a new diagnostic alternative (Tomás et al.,
2016, 2020). However, the relationship between serology and
the detection of P. jirovecii DNA in respiratory specimens is
not yet clear. In this topic, Tomás et al. presented an innovative
approach based on the development of a prototype for point-
of-care serological diagnosis of PCP. Synthetic multiepitope
antigens were designed, produced, and conjugated to gold
nanoparticles. They were used in the development of two
strip-based bionanodiagnostic assays for the specific detection of
IgM against P. jirovecii in patient sera. This technology may offer
an alternative to the conventional diagnosis of PCP, reducing the
use of invasive procedures in collecting respiratory specimens.
This new PCP diagnostic tool could be particularly useful in
low-income countries, where this disease is emerging.
PCP therapy remains a challenge. The contribution of
innate immunity to Pneumocystis-induced pathology is largely
unexplored. Excess mucus and goblet-cell-derived CLCA1
protein activation appear to be associated with Pneumocystis
infection in immunocompetent infants and animal models,
and innate immunity related airway mucus responses may
play a relevant role in the immunopathology of PCP. Existing
treatment of PCP depend on anti-Pneumocystis drugs plus
steroids that reduce cellular responses. Using a steroid-induced-
immunosuppression rat model of PCP, Pérez et al. documented
Pneumocystis-related pulmonary edema and progressive
goblet-cell-derived CLCA1-related immunopathology. After
the administration of the potent CLCA1-blocker Niflumic
acid there were progressive reversal of mucous changes and
improved animal survival. CLCA1 blockers could be used as an
adjunctive therapy to improve clinical outcome, especially in
steroid-induced PCP.
MICROSPORIDIA
Microsporidia have an environmental stage, the spore, which
contains a coiled polar tube anchored to the spore wall. It is
the developmental stage used in transmission of microsporidia
and invasion of host cells. Once the spores are ingested, the
polar tube inside ejects, delivering the sporoplasm into host cells
(Tamim El Jarkass and Reinke, 2020). The invasion mechanism
of microsporidia remains poorly explored. In the Research Topic,
Han B. et al. reviewed recent developments in the structure and
composition of the spore wall and polar tube and the invasion
process of microsporidia. The involvement of various polar tube
proteins in the invasion of host cells was discussed in detail.
Immune responses to microsporidia have attracted recent
attention. Studies in this area were done mostly with the three
human-pathogenic Encephalitozoon species, which have various
rodent models and can be cultured easily. Another review
by Han Y. et al. has summarized recent understandings of
the innate and acquired immune responses to microsporidia,
especially the role of various immune cells (macrophages,
dendritic cells, natural killer cells, etc.), the toll-like receptor-
MyD88 pathway in innate immunity, and antibody, CD4+
lymphocyte and CD8+ lymphocyte responses in acquired
immunity against microsporidia.
Enterocytozoon bieneusi is another major human-pathogenic
microsporidian species, responsible for over 90% human
microsporidiosis cases (Li and Xiao, 2021). Sequence analysis
of the ribosomal internal transcribed spacer (ITS) has identified
over 500 genotypes of various host ranges and zoonotic potential.
They belong to at least 11 genogroups, with Group 1 containing
most genotypes from humans andmany genotypes from animals.
Other groups have more restricted host ranges, therefore,
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representing host-adapted E. bieneusi populations. Therefore,
genetic characterizations of isolates have been used in studies of
the transmission dynamics, infection sources, and public health
significance of E. bieneusi in humans and animals (Li et al.,
2019). As a result, molecular epidemiology is a very active area
in microsporidiosis research (Matos et al., 2012).
In the collection of articles for the Research Topic, three of the
five ones on microsporidia were on molecular characterizations
of E. bieneusi, all from the same research group. Data from the
three studies suggest that domestic animals are infected with
diverse E. bieneusi genotypes. In a study conducted on seven
large-scale pig farms in Xinjiang, China by Li et al., a very
high prevalence (48.6% or 389/801) of E. bieneusi was found.
Altogether, 15 Group 1 genotypes were found, with the pig-
adapted genotypes EbpA (n = 129) and EbpC (n = 168) as
the dominant ones. These two genotypes and six other Group 1
genotypes were also found in a study by Zhao et al. of E. bieneusi
in racehorses. A low frequency (prevalence = 4.8% or 30/621)
of E. bieneusi was found in animals in 17 equestrian clubs in 15
Chinese cities. Among the E. bieneusi genotypes found, horse 1
(n = 16) was the dominant genotype. In addition to the Group
1 genotypes, one genotype each from Group 2 and Group 6 were
found in 1–2 animals. In contrast, in another report by Wang et
al., 11 E. bieneusi genotypes were found in dairy cattle (prevalence
= 14.2% or 501/3527) in three provinces in China, with two
bovine-adapted Group 2 genotypes I (n = 226) and J (n = 225)
as the dominant genotypes. Therefore, cattle, pigs and horses in
China are mostly infected with different groups of ITS genotypes
of E. bieneusi. This has important implications in understanding
cross-species transmission of E. bieneusi.
BLASTOCYSTIS
The pathogenicity of Blastocystis spp. remains controversial.
Some major contributors to this debate include the influences
of co-infections, microbiome, and subtype identity of Blastocystis
spp. (Deng et al., 2021). In one study presented in the Research
Topic by Betts et al., the subtype identity of Blastocystis spp.,
concurrence of Cryptosporidium spp., Eimeria spp., Isospora
spp., Entamoeba spp., and Giardia spp. were examined in 231
fecal samples collected from asymptomatic animals in two
conservation parks in the United Kingdom. Among the 38
vertebrate species examined, 47.4% (18/38) were positive for
Blastocystis spp. Altogether, 10 known subtypes were identified,
with ST2 as the most common one (31.4% or 80/255). Among
the animal species with significant Blastocystis-positive samples,
voles were mainly infected with ST4 (89.7% or 78/87), while
non-human primates were mostly infected with ST1 (24.8% or
27/109), ST2 (56.9% or 62/109), and ST3 (11.0% or 12/109). Of
the 81 Blastocystis-positive samples analyzed for other protists,
43 (53.1%) were positive for co-pathogens. These data suggest
that co-infection and subtype identity should be considered
in studies of pathogenicity of Blastocystis spp. in humans
and animals.
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